450 related articles for article (PubMed ID: 29081841)
1. Niraparib in ovarian cancer: results to date and clinical potential.
Caruso D; Papa A; Tomao S; Vici P; Panici PB; Tomao F
Ther Adv Med Oncol; 2017 Sep; 9(9):579-588. PubMed ID: 29081841
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibitors in ovarian cancer.
Ledermann JA
Ann Oncol; 2016 Apr; 27 Suppl 1():i40-i44. PubMed ID: 27141070
[TBL] [Abstract][Full Text] [Related]
3. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
[TBL] [Abstract][Full Text] [Related]
4. Niraparib for the treatment of ovarian cancer.
Kanjanapan Y; Lheureux S; Oza AM
Expert Opin Pharmacother; 2017 Apr; 18(6):631-640. PubMed ID: 28299955
[TBL] [Abstract][Full Text] [Related]
5. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
6. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
[No Abstract] [Full Text] [Related]
7. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
[TBL] [Abstract][Full Text] [Related]
8. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.
Sisay M; Edessa D
Gynecol Oncol Res Pract; 2017; 4():18. PubMed ID: 29214031
[TBL] [Abstract][Full Text] [Related]
10.
Mirza MR; Lindahl G; Mahner S; Redondo A; Fabbro M; Rimel BJ; Herrstedt J; Oza AM; Canzler U; Berek JS; González-Martín A; Follana P; Lord R; Azodi M; Estenson K; Wang Z; Li Y; Gupta D; Matulonis U; Feng B
Cancer Res Commun; 2022 Nov; 2(11):1436-1444. PubMed ID: 36970052
[TBL] [Abstract][Full Text] [Related]
11. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
[TBL] [Abstract][Full Text] [Related]
13. Niraparib: A Review in Ovarian Cancer.
Heo YA; Duggan ST
Target Oncol; 2018 Aug; 13(4):533-539. PubMed ID: 30073633
[TBL] [Abstract][Full Text] [Related]
14. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
15. Niraparib for the treatment of ovarian cancer.
Essel KG; Moore KN
Expert Rev Anticancer Ther; 2018 Aug; 18(8):727-733. PubMed ID: 29911447
[TBL] [Abstract][Full Text] [Related]
16. The role of niraparib for the treatment of ovarian cancer.
Ethier JL; Lheureux S; Oza AM
Future Oncol; 2018 Oct; 14(25):2565-2577. PubMed ID: 29856239
[TBL] [Abstract][Full Text] [Related]
17. Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations.
Xu Q; Li Z
Front Pharmacol; 2021; 12():743073. PubMed ID: 34912215
[TBL] [Abstract][Full Text] [Related]
18. PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
Gadducci A; Guerrieri ME
Anticancer Res; 2016 May; 36(5):2055-64. PubMed ID: 27127105
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of niraparib for
Kawamoto Y; Morizane C; Komatsu Y; Kondo S; Ueno M; Kobayashi S; Furukawa M; Lee L; Satoh T; Sakai D; Ikeda M; Imaoka H; Miura A; Hatanaka Y; Yokota I; Nakamura Y; Yoshino T
Future Oncol; 2024 Apr; ():1-7. PubMed ID: 38629456
[TBL] [Abstract][Full Text] [Related]
20. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]